µ±Ç°Î»ÖãºÊ×Ò³>×ÊѶ >ÉÌÎñóÒ× > ÃÀ¹úÉÌÒµ×ÊѶ>GEÒ½ÁƼ¯ÍÅÐû²¼Æä²ãÎöXÏßÈé·¿³ÉÏñ×éºÏ½â¾ö·½°¸SenoClaire»ñµÃÈÏÖ¤

GEÒ½ÁƼ¯ÍÅÐû²¼Æä²ãÎöXÏßÈé·¿³ÉÏñ×éºÏ½â¾ö·½°¸SenoClaire»ñµÃÈÏÖ¤

2013-07-17 ÔðÈα༭£ºÎ´Ìî ä¯ÀÀÊý£ºÎ´ÏÔʾ ÖÐóÉÌÍø-óÒ×ÉÌÎñ×ÊÔ´Íø

ºËÐÄÌáʾ£º¡¡¡¡ÓÉASiRDBTÇý¶¯¡¡¡¡·¨¹úBUC -- (ÃÀ¹úÉÌÒµ×ÊѶ) -- GEÒ½ÁƼ¯ÍÅ(NYSE: GE)½ñÌìÐû²¼£¬¸Ã¹«Ë¾ÅäÖÃÁËÈýά³ÉÏñ¼¼ÊõµÄÐÂÒ»´ú²ãÎöXÏßÈé

¡¡¡¡ÓÉASiRDBTÇý¶¯

¡¡¡¡·¨¹úBUC -- (ÃÀ¹úÉÌÒµ×ÊѶ) -- GEÒ½ÁƼ¯ÍÅ(NYSE: GE)½ñÌìÐû²¼£¬¸Ã¹«Ë¾ÅäÖÃÁËÈýά³ÉÏñ¼¼ÊõµÄÐÂÒ»´ú²ãÎöXÏßÈé·¿³ÉÏñ×éºÏ½â¾ö·½°¸SenoClaire*»ñµÃCEÈÏÖ¤£¬ÒÔ´Ë¿ª´´ÁËÈé·¿³ÉÏñµÄмÍÔª¡£SenoClaire¼¼ÊõÓÉASiR*DBT 1Çý¶¯£¬²ÉÓõͼÁÁ¿¶Ì³ÌXÉäÏߣ¬ÔÚ¶¨Î»ºóµÄÈé·¿ÖÜΧÒÔ“²½½øÕÕÏà”·¨É¨Ã裬Æعâ9´Î£¬Ïû³ýÁË¿ÉÄܵÄͼÏñ¶¶¶¯¡£

¡¡¡¡GEÒ½ÁƼ¯Íżì²â¼°µ¼Ïò½â¾ö·½°¸(DGS)Å®ÐÔ½¡¿µ²¿×ܾ­ÀíPrahlad Singh˵£º“±¾¹«Ë¾Å®ÐÔ½¡¿µÒµÎñÁìÓòµÄÕâÒ»ÖØÒª²úÆ·»ñµÃCEÈÏÖ¤£¬ÎÒÃǸе½·Ç³£¼¤¶¯¡£ÎÒÃDz»¶Ï´´Ð²úÆ·ÕóÈÝ£¬Ö¼ÔÚ°ïÖúÒ½Éú½«ÖÎÁÆÍØÕ¹µ½È«Çò¸ü¶àÅ®ÐÔ£¬´Ó¶ø°ïÖú¼õÉÙÈéÏÙ°©¡£ÎÒÃǵÄÄ¿±êÊÇÒýÁì±¾¹«Ë¾ÊýÂëXÏßÈé·¿³ÉÏñÁ½´óƽ̨µÄÒ»´ÎÉý¼¶½â¾ö·½°¸£¬¼´Senographe* EssentialºÍSenographe Care£¬´Ó¶øΪ¿Í»§ÌṩÁé»îÐÔ£¬ÒÔ±ãËûÃÇÄܹ»ÃæÏòÁÙ´²ºÍ»¼Õß¹¤×÷Á÷³ÌÀ´ÌáÉýÁÙ´²·þÎñ¡£”

¡¡¡¡¾«¶È¸ü¸ß¡¢ÐÅÐĸü×ã¡¢¼ÁÁ¿¸üµÍ£ºSenoClaire2

¡¡¡¡GEµÄSenoClaireÓÉASiRDBTÇý¶¯£¬¿ÉÌṩµ¥¸öMLOÊÓͼ£¬ÔÚÁÙ´²Éϲ»Ñ·ÓÚÁ½¸öÊÓͼµÄÊýÂëXÏßÈé·¿³ÉÏñ¼ì²é£¬µ«Ö»Ðè°ëÊý¼ÁÁ¿ºÍÒ»´ÎѹËõ¡£Òò´Ë£¬¸Ã½â¾ö·½°¸ÓÐÍûÔÚɸ²éÖÐÌæ´úÊýÂëXÏßÈé·¿³ÉÏñ¼ì²é£¬°ïÖú·ÅÉä¿ÆÒ½Éú¼ì²âÈéÏÙ°©¡£

¡¡¡¡´ËÍ⣬SenoClaire½«°ïÖúÌá¸ß½á¹¹±äÐκͰü¿é¼ì²âµÄÃô¸ÐÐÔ¡¢°ïÖúÌá¸ß²¡ÔîÔµÊÓ¼ìµÄÌØÒìÐÔ£¬²¢Í¨¹ý¸üºÃµØ¶¨ÐÔ¼ì²â½á¹û£¬**ÖÕ°ïÖú·ÅÉä¿ÆÒ½Éú½µµÍ¸´¼ìÂÊ¡£**ºó£¬ÆäͼÏñÓëÖ÷Á÷µÄPACSϵͳ¼æÈÝ£¬Òò´Ë£¬·ÅÉä¿ÆÒ½ÉúºÜÈÝÒ×½«ÕâЩͼÏñÕûºÏµ½×Ô¼ºµÄ»·¾³ÖУ¬´Ó¶ø»ñµÃ**µÄͶ×ÊÊÕÒæ3¡£

¡¡¡¡Ê×Åú·¢»õÒÑÔÚÅ·ÖÞ¡¢Öж«¡¢°Ä´óÀûÑǺÍÀ­ÃÀ¿ªÊ¼£¬¿Í»§µ¥Î»µÄ¶©µ¥·×ÖÁí³À´¡£

¡¡¡¡GEÒ½ÁƼ¯Íżì²â¼°µ¼Ïò½â¾ö·½°¸(DGS)×ܲüæÊ×ϯִÐйÙHooman Hakami×ܽáµÀ£º“GEÒ½ÁƼ¯ÍÅÔÚÈéÏÙ°©ÖÎÁÆÁìÓòÓµÓÐ**¹ã·ºµÄ½â¾ö·½°¸ÕóÈÝ£¬¸²¸ÇÓ²¼þ¡¢Èí¼þºÍÊÔ¼Á£¬ÎÒÃDz»¶Ï½«´´ÐÂÒý½øÈéÏÙ°©ÖÎÁÆÁìÓò£¬ÒÔ²»Í¬Ñ°³£µÄ·½Ê½½«ËüÃÇÕûºÏÆðÀ´¡£Ëæ×ÅSenoClaire*µÄÒý½ø£¬ÎÒÃÇÕýÔÚÍƳöÐÂÒ»´ú²ãÎöXÏßÈé·¿³ÉÏñ×éºÏ£¬Óë´Ëͬʱ»¹ÓÐһЩ´´Ð½â¾ö·½°¸£¬ÀýÈçÔìÓ°¼ÁÔöÇ¿¹âÆ**â°ÐXÏßÈé·¿³ÉÏñ¡¢È«Èé·¿×Ô¶¯»¯³¬ÉùºÍ·Ö×ÓÈé·¿³ÉÏñ¡£ÎÒÃǵÄÄ¿±êÊÇΪ½¡¿µÌṩÕß×°±¸**ÆëÈ«µÄ¹¤¾ß¿â£¬ÔÚÖÎÁÆÈ«³ÌµÄÿһ¸öÕ¾µã°ïÖúµ½»¼Õß¡£”

¡¡¡¡-ÖÕ-

¡¡¡¡×¢£º

¡¡¡¡*ͨÓõçÆø¹«Ë¾µÄÉ̱ꡣ

¡¡¡¡SenoClaireδ»ñµÃFDAºË×¼¡£²¢·ÇËùÓеØÇø¶¼ÓÐSenoClaire¹©»õ¡£

¡¡¡¡¹ØÓÚGEÒ½ÁƼ¯ÍÅ

¡¡¡¡GEÒ½ÁƼ¯ÍÅÌṩ¸ïÐÂÐÔµÄÒ½ÁƼ¼ÊõºÍ·þÎñ£¬ÒÔÂú×ãÐèÇó£¬Ê¹È«**¸ü¶àµÄÈËÄܹ»ÒÔ¸ü¿É¸ºµ£µÄ³É±¾»ñµÃ¸üºÃµÄÒ½ÁÆ·þÎñ¡£GE(ŦԼ֤½»Ëù£ºGE)רעÓÚ**ÖÁ¹ØÖØÒªµÄÎÊÌ⣬ÒÔÓÅÐãÈ˲źÍ**¼¼ÊõÖÂÁ¦ÓÚÓ¦¶ÔÐÐÒµÖØ´óÌôÕ½¡£GEÒ½ÁƼ¯ÍÅÔÚҽѧ³ÉÏñ¡¢Èí¼þºÍÐÅÏ¢¼¼Êõ¡¢»¼Õ߼໤ºÍÕï¶Ï¡¢Ò©ÎïÑз¢¡¢ÉúÎïÖÆÒ©¼¼Êõ¡¢×¿Ô½ÔËÓª½â¾ö·½°¸µÈ¶à¸öÁìÓò£¬ÖúÁ¦×¨ÒµÒ½ÎñÈËԱΪ»¼ÕßÌṩ**µÄÒ½ÁÆ·þÎñ¡£

¡¡¡¡1 SenoClaire uses ASiRDBT, an iterative reconstruction algorithm that yields FFDM-like images and positively impacts micro calcification conspicuity. [SenoClaire²ÉÓÃASiRDBT£¬ÕâÊÇÒ»ÖÖµü´úÖؽ¨Ëã·¨£¬¿ÉÉú³ÉÀàËÆFFDMµÄͼÏñ£¬¶Ô΢¸Æ»¯ÔîµÄ¿ÉÊÓÐÔÓлý¼«Ó°Ïì]

¡¡¡¡2 1GE190-004 BIE (Blinded Imaging Evaluation) study – US. A Multicenter Study to Test the Non-Inferiority of Digital Breast Tomosynthesis Compared to FFDM in Detecting Breast Cancer [1GE190-004 BIE(ä̬ͼÏñÆÀ¹À)Ñо¿– ÃÀ¹ú¡£²âÊÔÊýÂë²ãÎöXÏßÈé·¿³ÉÏñ×éºÏ¼ì²âÈéÏÙ°©²»Ñ·ÓÚFFDMµÄ¶àÖÐÐÄÑо¿]

¡¡¡¡ÃâÔðÉùÃ÷£º±¾¹«¸æÖ®Ô­ÎÄ°æ±¾ÄË**ÊÚȨ°æ±¾¡£ÒëÎĽö¹©·½±ãÁ˽âÖ®Ó㬷³Çë²ÎÕÕÔ­ÎÄ£¬Ô­ÎÄ°æ±¾ÄË**¾ß·¨ÂÉЧÁ¦Ö®°æ±¾¡£

¡¡¡¡ÁªÏµ·½Ê½£º

¡¡¡¡GEÒ½ÁƼ¯ÍÅ

¡¡¡¡¼ì²â¼°µ¼Ïò½â¾ö·½°¸(DGS)È«Çò´«²¥¾­ÀíPilar Anton Serrano

¡¡¡¡+33665874751

¡¡¡¡pilar.antonserrano@ge.com

·ÖÏíµ½£º
ÔĶÁÉÏÎÄ >> ½ø¿ÚҺ̬ÄÌÊÜ×·Åõ ²¿·Ö"ÑóÅ£ÄÌ"ÔÚÔ­²úµØÊÇ·ÇÖ÷Á÷
ÔĶÁÏÂÎÄ >> IIÆÚÁÙ´²Êý¾ÝÏÔʾ£¬Ñ¡ÔñÐÔ5-HT6ÊÜÌåÞ׿¹¼ÁLu AE58054ÁªºÏ¶àÄÎßßÆë¶Ô°¢¶û´Äº£Ä¬²¡ÈÏÖªÖ¢×´µÄ¸ÄÉÆЧ¹ûÓÐͳ¼ÆѧÒâÒå

´ó¼Òϲ»¶¿´µÄ

  • Æ·ÅÆ
  • ×ÊѶ
  • Õ¹»á
  • ÊÓƵ
  • ͼƬ
  • ¹©Ó¦
  • Çó¹º
  • É̳Ç

°æȨÓëÃâÔðÉùÃ÷£º

·²×¢Ã÷¸å¼þÀ´Ô´µÄÄÚÈݾùΪתÔظå»òÓÉÆóÒµÓû§×¢²á·¢²¼£¬±¾ÍøתÔسöÓÚ´«µÝ¸ü¶àÐÅÏ¢µÄÄ¿µÄ£»ÈçתÔظåÉæ¼°°æȨÎÊÌ⣬Çë×÷ÕßÁªÏµÎÒÃÇ£¬Í¬Ê±¶ÔÓÚÓû§ÆÀÂÛµÈÐÅÏ¢£¬±¾Íø²¢²»Òâζ×ÅÔÞͬÆä¹Ûµã»ò֤ʵÆäÄÚÈݵÄÕæʵÐÔ£»


±¾ÎĵØÖ·£ºhttp://news.ceoie.com/show-175902.html

תÔر¾Õ¾Ô­´´ÎÄÕÂÇë×¢Ã÷À´Ô´£ºÖÐóÉÌÍø-óÒ×ÉÌÎñ×ÊÔ´Íø

΢ÐÅ¡°É¨Ò»É¨¡±
¼´¿É·ÖÏí´ËÎÄÕÂ

ÓÑÇéÁ´½Ó

·þÎñÈÈÏߣº0311-89210691 ICP±¸°¸ºÅ£º¼½ICP±¸2023002840ºÅ-2